NCCN Guidelines Insights: Bone Cancer, Version 2.2017
Journal of the National Comprehensive Cancer Network2017Vol. 15(2), pp. 155–167
Citations Over TimeTop 1% of 2017 papers
J. Sybil Biermann, Warren Chow, Damon R. Reed, David R. Lucas, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian E. Brigman, G. Thomas Budd, William T. Curry, Aarati Didwania, Nicola Fabbri, Francis J. Hornicek, Joseph Kuechle, Dieter M. Lindskog, Joel Mayerson, Sean V. McGarry, Lynn Million, Carol D. Morris, Sujana Movva, Richard J. O’Donnell, R. Lor Randall, Peter S. Rose, Victor M. Santana, Robert L. Satcher, Herbert S. Schwartz, Herrick J. Siegel, Katherine A. Thornton, Víctor M. Villalobos, Mary Anne Bergman, Jillian L. Scavone
Abstract
The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed.
Related Papers
- → Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients(2007)112 cited
- → Endoscopic Endonasal Surgery for Clival Chordoma and Chondrosarcoma(2008)60 cited
- → Feasibility of Proton Beam Therapy for Chordoma and Chondrosarcoma of the Skull Base(2011)47 cited
- → Low-Grade Spinal Malignancies: Chordoma and Chondrosarcoma(2020)2 cited
- → LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas(2022)2 cited